ABSTRACT
A hanseníase é uma doença infecto-contagiosa, granulomatosa de evolução crônica, causada pelo Mycobacterium leprae. A introdução da poliquimiterapia pela Organização Mundial da Saúde em 1981, resultou na cura de milhões de indivíduos infectados pelo bacilo, no entanto ela ainda é considerada endêmica e negligenciada em países como o Brasil. A indústria farmacêutica não tem mostrado interesse em investir na pesquisa de novos fármacos, porém novas opções terapêuticas são importantes para o controle da endemia. Uma das alternativas de terapia para infecções que são causadas por microrganismos intracelulares é o bloqueio de ferro. Este metal tem grande importância na replicação dos patógenos no hospedeiro então, o uso de quelantes para a redução da carga parasitaria é uma das possibilidades estudadas. Um dos compostos utilizados como quelante do ferro é o mesilato de desferroxamina (DFX), que tem atividade antimicrobiana e vem sendo estudado no tratamento de diversas doenças como a talassemia. O maltolato de gálio também é um quelante capaz de se ligar ao ferro, competindo em sua via metabólica. O objetivo do estudo foi avaliar o efeito do DFX, administrado sozinho ou em associação com o maltolato de gálio, na replicação do Mycobacterium leprae em modelo experimental murino. Os camundongos infectados foram divididos em três grupos (controle, DFX e DFX + gálio) e o tratamento teve início 60 dias após a inoculação sendo administrado por 90 dias. Os animais receberam ração com restrição de ferro e água ad libitum. A suspensão do maltolato de gálio (150mg/kg) foi administrada diariamente via oral por gavage. O DFX foi aplicado por via intraperitoneal na concentração de 10 mg/kg, uma vez por semana durante cinco semanas. Os camundongos foram eutanasiados após 150 e 240 dias após inoculação. Em relação ao primeiro tempo de eutanásia (150 dias), não houve diferença estatisticamente significativa entre o número de bacilos recuperados entre o controle e os animais tratados; após 240 dias, houve diferença estatisticamente significativa (p<0,05) entre o número de bacilos recuperados entre o grupo controle e os animais tratados com DFX e DFX + gálio oral (p<0,0088 e p<0,0032 respectivamente). Os resultados mostraram que o uso de quelantes de ferro como o DFX e o gálio oral não impediram a replicação do bacilo, mas contribuiram para a diminuição da quantidade recuperada (carga bacilar).
Leprosy is an infectious, contagious, granulomatous disease of chronic evolution, caused by Mycobacterium leprae. The introduction of multidrug therapy by the World Health Organization in 1981 resulted in the cure of millions of individuals infected by the bacillus, however it is still considered endemic and neglected in countries like Brazil. The pharmaceutical industry has not shown interest in investing in the research of new drugs, but new therapeutic options are important for controlling the endemic disease. One of the therapy alternatives for infections that are caused by intracellular microorganisms is iron blockade. This metal is of great importance in the replication of pathogens in the host, so the use of chelators to reduce the parasite load is one of the possibilities studied. One of the compounds used as a iron chelator is desferrioxamine mesylate (DFX), which has antimicrobial activity and has been studied in the treatment of various diseases such as thalassemia. Gallium maltolate is also a chelator capable of binding to iron, competing in its metabolic pathway. The objective of the study was to evaluate the effect of DFX, administered alone or in association with gallium maltolate, on the replication of Mycobacterium leprae in a murine experimental model. Infected mice were divided into 3 groups (control, DFX and DFX + gallium) and treatment started 60 days after inoculation and was administered for 90 days. The animals received iron-restricted chow and water ad libitum. The suspension of gallium maltolate (150mg/kg) was administered orally daily by gavage. DFX was applied intraperitoneally at a concentration of 10 mg/kg, once a week for five weeks. The mice were euthanized after 150 and 240 days after inoculation. Regarding the first time of euthanasia (150 days), there was no statistically significant difference between the number of bacilli recovered between the control and treated animals; after 240 days, there was a statistically significant difference (p<0.05) between the number of bacilli recovered between the control group and the animals treated with DFX and DFX + oral gallium (p<0.0088 and p<0.0032 respectively). The results showed that the use of iron chelators such as DFX and oral gallium did not prevent the bacillus from replicating, but contributed to a decrease in the amount recovered (bacillary load).
Subject(s)
Animals , Mice , Deferoxamine/therapeutic use , Gallium/therapeutic use , Mycobacterium leprae/drug effects , Leprosy , Mice, Inbred BALB CABSTRACT
BACKGROUND: Leprosy relapse/recurrence is a serious concern particularly in a leprosy-endemic nation such as India. It is believed that bacilli persisting even after multidrug therapy can cause relapse; recently, however, drug resistance as a cause for recurrences and chronic erythema nodosum leprosum (ENL) has been speculated. AIM: To study drug-resistance patterns in cases of leprosy relapse and chronic/recurrent (c/r)ENL. METHODS: This cross-sectional study conducted over a period of 1 year included patients diagnosed as having leprosy relapse and those with c/rENL. Skin biopsy specimens were examined by conventional PCR for resistance testing for rifampicin, dapsone and ofloxacin, respectively targeting the rpoB, folP and gyrA genes of Mycobacterium leprae. RESULTS: In total, 61 patients (25 smear-negative) were included in the study. Of these, 37 were diagnosed as having leprosy relapse and 24 as having c/rENL. Drug resistance to at least one drug was identified in 10 cases (16.4%). Rates of drug resistance were 5.4% (2 of 37) for dapsone, 10.8% (4 of 37) for rifampicin and 2.7% (1 of 37) for ofloxacin among cases of relapse, whereas it was 12.5% (3 of 24) and 8.3% (2 of 24) for dapsone and rifampicin respectively among those with c/rENL. Multidrug resistance was seen in 3.3% patients (2 of 61). CONCLUSION: Drug-resistance rate among those with c/rENL was almost equalled that of relapse. Smear-negative leprosy relapse cases also had resistance to bactericidal drugs. These findings call for modifications in criteria for testing under leprosy drug-resistance surveillance and all cases of relapse and those with recalcitrant c/rENL should be tested.
Subject(s)
Drug Resistance, Bacterial , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Mycobacterium leprae/drug effects , Adult , Chronic Disease , Cross-Sectional Studies , Drug Resistance, Bacterial/genetics , Drug Resistance, Multiple, Bacterial , Endemic Diseases , Female , Humans , Male , Middle Aged , RecurrenceABSTRACT
BACKGROUND: Regarding the leprosy transmission through the upper airways, overcrowded locations such as prisons can become a risk to get sick. Like the leprosy hidden endemic demonstrated in male prison population, being interesting to assess the leprosy scene also among confined women. METHODS: A prospective descriptive study conducted at Female Penitentiary, Brazil. Leprosy Suspicion Questionnaire (LSQ) were applied to the participants, and submitted to specialized dermatoneurological exam, peripheral nerve ultrasonography, and anti-PGL-I serology. FINDINGS: 404 female inmates were evaluated, 14 new cases were diagnosed (LG-leprosy group), a new case detection rate (NCDR) of 3.4%, 13 multibacillary, while another 390 constituted the Non-Leprosy group (NLG). Leprosy cases were followed up during multidrug therapy with clinical improvement. The confinement time median was 31 months in LG, similar to NLG, less than the time of leprosy incubation. Regarding LSQ, the neurological symptoms reached the highest x2 values as Q1-numbness (5.6), Q3-anesthetizes areas in the skin (7.5), Q5-Stinging sensation (5.8), and Q7-pain in the nerves (34.7), while Q4-spots on the skin was 4.94. When more than one question were marked in the LSQ means a 12.8-fold higher to have the disease than a subject who marked only one or none. The high 34% rate of anti-PGL-I seropositivity in the penitentiary, higher levels in LG than NLG. Three additional leprosy cases each were diagnosed on the second (n = 66) and third (n = 14) reevaluations 18 and 36 months after the initial one. Semmes-Weinstein monofilaments demonstrated lower limbs (32.2%) more affected than the upper limbs (25%) with improvement during the follow-up. INTERPRETATION: The NCDR in this population showed an hidden endemic of leprosy as well as the efficacy of a search action on the part of a specialized team with the aid of the LSQ and anti-PGL-I serology as an auxiliary tracking tools.
Subject(s)
Leprosy/diagnosis , Prisons/statistics & numerical data , Adult , Brazil/epidemiology , Female , Follow-Up Studies , Humans , Leprostatic Agents/adverse effects , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Leprosy/epidemiology , Leprosy/microbiology , Middle Aged , Mycobacterium leprae/drug effects , Mycobacterium leprae/physiology , Prospective Studies , Young AdultABSTRACT
ABSTRACT: Cured leprosy patients have special physical conditions, which could pose challenges for safety and immunogenicity after immunization. We performed an observational clinical study aimed to identify the safety and immunogenicity of influenza vaccine in cured leprosy patients. A total of 65 participants from a leprosarium were recruited into leprosy cured group or control group, and received a 0.5âml dose of the inactivated split-virion trivalent influenza vaccine and a follow-up 28âdays proactive observation of any adverse events. Hemagglutination and hemagglutination inhibition test was performed to evaluate serum antibody titer, flow cytometry was conducted to screen of cytokines level. The total rate of reactogenicity was 0.0% [0/41] in leprosy cured group and 37.5% [9/24] in control group. The seroconversion rate for H1N1 was difference between leprosy cured group and control group (41.83% vs 79.17%, Pâ=â.0082), but not for H3N2 (34.25% vs 50.00%, Pâ=â.4468). At day 0, leprosy cured group have relatively high concentration of interleukin-6, interleukin-10, tumor necrosis factor, interferon-γ, and interleukin-17 compared to control group. The interleukin-2 concentration increased 2 weeks after vaccination compared to pre-vaccination in leprosy cured group, but declined in control group (0.92âpg/ml vs -0.02âpg/ml, Pâ=â.0147). Leprosy cured group showed a more rapid down-regulation of interleukin-6 when influenza virus was challenged compared to control group (-144.38âpg/ml vs -11.52âpg/ml, Pâ<â.0001). Subgroup analysis revealed that the immunization administration declined interleukin-17 concentration in Tuberculoid type subgroup, but not in Lepromatous type subgroup or control group. Clinically cured leprosy patients are relatively safe for influenza vaccine. Leprosy cured patient have immune deficit in producing antibody. Interleukin-6 and interleukin-17 were 2 sensitive indicators in immune response for leprosy affected patients. The identification of indicators might be help management of leprosy and used as predictive markers in leprosy early symptom monitoring.
Subject(s)
Immunity/drug effects , Immunogenicity, Vaccine , Influenza Vaccines/standards , Leprosy/drug therapy , Antibody Formation/drug effects , Humans , Influenza A Virus, H1N1 Subtype/drug effects , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/drug effects , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/adverse effects , Influenza Vaccines/therapeutic use , Leprosy/immunology , Mycobacterium/drug effects , Mycobacterium/pathogenicity , Mycobacterium leprae/drug effects , Mycobacterium leprae/pathogenicityABSTRACT
Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae and the treatment of choice is ofloxacin (OFX). Specific amino acid substitutions in DNA gyrase of M. leprae have been reported leading to resistance against the drug. In our previous study, WQ-3810, a fluoroquinolone with a new R1 group (6-amino-3,5-difluoropyridin-2-yl) was shown to have a strong inhibitory activity on OFX-resistant DNA gyrases of M. leprae, and the structural characteristics of its R1 group was predicted to enhance the inhibitory activity. Methodology/Principal Finding: To further understand the contribution of the R1 group, WQ-3334 with the same R1 group as WQ-3810, WQ-4064, and WQ-4065, but with slightly modified R1 group, were assessed on their activities against recombinant DNA gyrase of M. leprae. An in silico study was conducted to understand the molecular interactions between DNA gyrase and WQ compounds. WQ-3334 and WQ-3810 were shown to have greater inhibitory activity against M. leprae DNA gyrase than others. Furthermore, analysis using quinolone-resistant M. leprae DNA gyrases showed that WQ-3334 had greater inhibitory activity than WQ-3810. The R8 group was shown to be a factor for the linkage of the R1 groups with GyrB by an in silico study. Conclusions/Significance: The inhibitory effect of WQ compounds that have a new R1 group against M. leprae DNA gyrase can be enhanced by improving the binding affinity with different R8 group molecules. The information obtained by this work could be applied to design new fluoroquinolones effective for quinolone-resistant M. leprae and other bacterial pathogens.
Subject(s)
Anti-Bacterial Agents/pharmacology , DNA Gyrase/genetics , Drug Resistance, Multiple, Bacterial/genetics , Mycobacterium leprae/drug effects , Mycobacterium leprae/genetics , Quinolones/pharmacology , Azetidines/pharmacology , Fluoroquinolones/pharmacology , Genes, Bacterial , Microbial Sensitivity TestsABSTRACT
The World Health Organization has raised concerns about the increasing number of Hansen disease (HD) relapses worldwide, especially in Brazil, India, and Indonesia that report the highest number of recurrent cases. Relapses are an indicator of MDT effectiveness and can reflect Mycobacterium leprae persistence or re-infection. Relapse is also a potential marker for the development or progression of disability. In this research, we studied a large cohort of persons affected by HD treated with full fixed-dose multibacillary (MB) multidrug therapy (MDT) followed for up to 20 years and observed that relapses are a rare event. We estimated the incidence density of relapse in a cohort of patients classified to receive MB regime (bacillary index (BI) > 0), diagnosed between September 1997 and June 2017, and treated with twelve-dose MB-MDT at a HD reference center in Rio de Janeiro, Brazil. We obtained the data from the data management system of the clinic routine service. We linked the selected cases to the dataset of relapses of the national HD data to confirm possible relapse cases diagnosed elsewhere. We diagnosed ten cases of relapse in a cohort of 713 patients followed-up for a mean of 12.1 years. This resulted in an incidence rate of 1.16 relapse cases per 1000 person-year (95% CI = 0.5915-2.076). The accumulated risk was 0.025 in 20 years. The very low risk observed in this cohort of twelve-dose-treated MB patients reinforces the success of the current MDT scheme.
Subject(s)
Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , Child , Child, Preschool , Clofazimine/therapeutic use , Dapsone/therapeutic use , Drug Therapy, Combination , Female , Humans , Incidence , Male , Middle Aged , Mycobacterium leprae/drug effects , Recurrence , Retrospective Studies , Rifampin/therapeutic use , Skin/microbiology , Skin/pathology , Young AdultABSTRACT
Introdução: O diagnóstico da hanseníase possui números significativos que causam preocupação à saúde pública. Os casos de resistência medicamentosa nessa doença se iniciaram em meados dos anos 60 e diante do problema, a Organização Mundial da Saúde instituiu em 1981 a poliquimioterapia, associação dos antibióticos rifampicina, dapsona e clofazimina, tratamento atual de escolha. A resistência aos fármacos na hanseníase é reportada pela literatura, desvelando um obstáculo à sua eliminação. Apresentamos nessa revisão os principais aspectos da resistência medicamentosa no tratamento para hanseníase e seus impactos. Metodologia: Revisão sistemática sobre os aspectos da resistência medicamentosa utilizando a pesquisa exploratória como metodologia de abordagem. Foram pesquisados os termos resistência medicamentosa, hanseníase, recidiva, alterações genéticas e os operadores booleanos "and" e "or" na busca. Resultados e discussão: A dificuldade de tomar a medicação corretamente foi um dos principais fatores que acarretaram resistência do bacilo Mycobacterium leprae aos fármacos. Homens de países norte e sul-americanos e asiáticos foram os mais atingidos por episódios de resistência. A resistência medicamentosa é uma das principais causas de recidivas em hanseníase. O principal fármaco causador de resistência medicamentosa descrito nos trabalhos foi a dapsona (46,6%) e a maioria das alterações genéticas encontradas estão no gene rpoB; 23,2% dos registros relatados foram de resistência secundária aos fármacos e, também, sete casos de resistência múltipla a esses medicamentos. Conclusão: Os principais aspectos da resistência medicamentosa na hanseníase são os equívocos ao ingerir os medicamentos e as alterações genéticas na bactéria. Os impactos causados estão na dificuldade de refazer o tratamento, a possibilidade de nova transmissão e o aparecimento de sintomas mais graves.
Introduction: The diagnosis of leprosy has significant numbers causing public health concern. Reports of drug resistance in this disease begun in the mid-1960s and due to this problem, the World Health Organization instituted a multidrug therapy with rifampicin, dapsone, and clofazimine antibiotic association in 1981, which is currently the first-choice treatment for leprosy. Cases of drug resistance have been reported in literature, revealing an obstacle to the eradication of the disease. This paper has the purpose of presenting the key aspects and impacts of drug resistance in the treatment for leprosy. Methods: Systematic review of the drug resistance aspects using exploratory research as an approach methodology. The authors searched the terms drug resistance, leprosy, recurrence, genetic alterations, and the Boolean operators "and" and "or" between them. Results and discussion: The difficulty in taking the medication correctly was one of the key factors that led to drug resistance for Mycobacterium leprae. Men from North and South American, as well as from Asian countries, were the most affected by episodes of resistance. Drug resistance is one of the main causes of leprosy recurrences. Dapsone was the most frequently identified drug resistance in the studies (46.6%), while most of the genetic alterations were found in the rpoB gene; 23.2% of the cases were from secondary resistance episodes, and seven cases of multiple resistance were reported. Conclusion: The misconceptions when taking the treatment and the Mycobacterium leprae genetic alterations have been described as the key aspects of drugs resistance in leprosy and the impacts caused are the difficulty in redoing the treatment, the possibility of new transmission, and the appearance of more severe symptoms.
Subject(s)
Drug Resistance/drug effects , Drug Resistance, Bacterial/drug effects , Mycobacterium leprae/drug effects , Rifampin/adverse effects , Bacteria/genetics , Pharmaceutical Preparations , Clofazimine/adverse effects , Fluoroquinolones/adverse effects , Dapsone/adverse effects , Drug Therapy, Combination/adverse effects , Leprosy/drug therapy , Anti-Bacterial Agents/adverse effectsABSTRACT
Although multidrug therapy is considered an effective treatment for leprosy, antimicrobial resistance is a serious concern. We performed a systematic review of studies on the diagnostic accuracy and screening of tests for antimicrobial resistance in leprosy. This review was registered in PROSPERO (CRD42020177958). In April 2020, we searched for studies in the PubMed, EMBASE, Web of Science, Scopus, Scielo, and LILACS databases. A random effects regression model was used for the meta-analysis. We included 129 studies. Molecular tests for dapsone resistance had a sensitivity of 78.8% (95% confidence interval [CI] = 65.6-87.9) and a specificity of 97.0% (95% CIâ¯=â¯94.0-98.6). Molecular tests for rifampicin resistance had a sensitivity and specificity of 88.7% (95% CIâ¯=â¯80.0-93.9) and 97.3% (95% CIâ¯=â¯94.3-98.8), respectively. Molecular tests for ofloxacin resistance had a sensitivity and specificity of 80.9% (95% CIâ¯=â¯60.1-92.3) and 96.1% (95% CIâ¯=â¯90.2-98.5), respectively. In recent decades, no increase in the resistance proportion was detected. However, the growing number of resistant cases is still a clinical concern.
Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Leprosy , Microbial Sensitivity Tests , Mycobacterium leprae/drug effects , DNA, Bacterial/genetics , Humans , Leprosy/diagnosis , Leprosy/microbiology , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/standards , Sensitivity and Specificity , Sequence Analysis, DNAABSTRACT
A hanseníase é uma doença infectocontagiosa crônica causada pelo Mycobacterium leprae (M. leprae). Manifesta-se, principalmente, por lesões de pele com alteração de sensibilidade térmica, dolorosa e tátil, decorrentes da predileção de seu agente etiológico por células cutâneas e nervosas periféricas. No mundo, em 2018, foram reportados à Organização Mundial da Saúde (OMS), 208.619 casos novos; desses, 28.660 foram notificados no Brasil, sendo o segundo país com maior número detectado. Acredita-se que a transmissão e infecção ocorram através de secreções provenientes das vias aéreas superiores, pelo contato íntimo e prolongado de indivíduo suscetível com paciente multibacilar sem tratamento, por meio da inalação dos bacilos. O tratamento preconizado pela OMS consiste na associação de três medicamentos dapsona (DDS), rifampicina (RFP) e clofazimina (CLO) com o objetivo de atuar na prevenção da seleção de cepas mutantes do M. leprae resistentes a uma ou mais drogas utilizadas. A ofloxacina (OFLO) é usada como esquema alternativo ao tratamento padrão, associando-se a RFP e CLO, sendo útil nos casos de resistência medicamentosa ou intolerância a uma das drogas. O bacilo não se reproduz em meios de cultura artificiais ou celulares obstáculo para o avanço em estudos do patógeno. Em 1960, Charles Shepard, demonstrou pela primeira vez a multiplicação do M. leprae em coxim plantar de camundongo imunocompetente, técnica considerada marco na pesquisa do bacilo, propiciando a verificação de sua viabilidade e uma possível resistência às drogas utilizadas no tratamento da doença. O presente estudo teve como objetivo validar o método fenotípico, por meio da inoculação do bacilo em coxim plantar posterior de camundongos imunocompetentes da linhagem BALB/c (técnica de Shepard), para detecção de sensibilidade à CLO e OFLO. Os animais foram inoculados com suspensão de bacilos obtidos de camundongos nude mouse atímicos previamente infectados com a cepa Thai53, que possui perfil genético de sensibilidade às drogas, e divididos em grupo controle (não tratado), RFP (10mg/kg), CLO (50mg/kg) e OFLO (150mg/kg). Após cinco meses de inoculação e tratamento, os animais foram eutanasiados, e os coxins excisados para contagem do número de bacilos e análise histopatológica. No grupo controle, o número de bacilos recuperados foi maior que 1,0x105 /coxim, compatível com multiplicação bacilar; a análise histopatológica evidenciou infiltrado inflamatório intenso com bacilos agrupados ou em globias, íntegros e bem corados. Nos grupos tratados, não foi observada evidência de multiplicação bacilar, mostrando sensibilidade às drogas testadas; a análise histopatológica evidenciou infiltrado inflamatório discreto a moderado com ausência de bacilos. A técnica de Shepard é considerada padrão ouro para a multiplicação do bacilo, sendo fundamental para validar a identificação de novos alvos de mutação em genes determinantes da ação das drogas anti-hansênicas. Os resultados gerados no presente estudo terão grande impacto, principalmente para compreender a falha terapêutica em pacientes com recidiva que não apresentaram perfil de resistência pelos mecanismos moleculares até o momento descritos para a doença.
Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). It is mainly manifested by skin lesions with changes in thermal, sensory and tactile sensitivity resulting from the predilection of its etiologic agent by skin and peripheral nerve cells. The World Health Organization (WHO) reported 208,619 new cases in 2018 worldwide; among these, 28,660 were reported in Brazil, the second country with the highest number detected. It is believed that transmission and infection occur by inhaling bacilli through the upper airways, while in close and prolonged contact of a susceptible individual with an untreated multibacillary patient. The treatment recommended by the WHO consists of the combination of three drugs -dapsone (DDS), rifampicin (RFP) and clofazimine (CLO) - in order to prevent the selection of mutant M. leprae strains resistant to one or more drugs. Ofloxacin (OFLO) is used as an alternative regimen to standard treatment, in association with RFP and CLO, being useful in cases of drug resistance or intolerance to one of the drugs. The bacillus does not reproduce in artificial or cellular culture media - an obstacle to progress in studies of the pathogen. In 1960, Charles Shepard, demonstrated for the first time the multiplication of M. leprae in an immunocompetent mouse footpad, a technique considered a landmark in the bacillus research, enabling the verification of its viability and a possible resistance to drugs used in the treatment of the disease. The present study aimed to validate the phenotypic method, by inoculating the bacillus in the hind footpads of immunocompetent BALB/c mice strain (Shepard's technique), to detect sensitivity to CLO and OFLO. The animals were inoculated with a suspension of bacilli obtained from athymic nude mouse previously infected with the Thai-53 strain, a sensitive strain. Mice were divided into a control (untreated), RFP (10mg / kg), CLO (50mg / kg) and OFLO (150mg / kg) groups. After five months of inoculation and treatment, the animals were euthanized and the foopads excised for enumeration of bacilli and histopathological analysis. In the control group, the number of bacilli recovered was greater than 1.0x105 /footpad, compatible with bacillary multiplication; histopathological analysis showed an intense inflammatory infiltrate with well stained grouped bacilli and globi. In the treated groups, there was no evidence of bacillary multiplication, showing sensitivity to the drugs tested; histopathological analysis showed mild to moderate inflammatory infiltrate with no bacilli. The Shepard technique is considered the gold standard for bacillus multiplication, being essential to validate the identification of new mutation targets in genes that determine anti-leprosy drugs activity. The results generated in the present study will have a great impact, mainly to understand the therapeutic failure in patients with recurrence who did not present a resistance profile using molecular mechanisms described so far for the disease.
Subject(s)
Leprosy/therapy , Mycobacterium leprae/drug effects , Drug Resistance , Ofloxacin/therapeutic use , Clofazimine/therapeutic useSubject(s)
Insecticides/administration & dosage , Leprostatic Agents/administration & dosage , Leprosy, Lepromatous/diagnosis , Mycobacterium leprae/drug effects , Sarcoptes scabiei/drug effects , Scabies/diagnosis , Adult , Animals , Clofazimine/administration & dosage , Humans , Ivermectin/administration & dosage , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/microbiology , Leprosy, Lepromatous/pathology , Male , Neglected Diseases , Permethrin/administration & dosage , Rifampin/administration & dosage , Scabies/drug therapy , Scabies/parasitology , Scabies/pathology , Skin/microbiology , Skin/parasitology , Skin/pathology , Tropical MedicineABSTRACT
Molecular epidemiology investigations are notoriously challenging in the leprosy field mainly because the inherent characteristics of the disease as well as its yet uncultivated causative agents, Mycobacterium leprae and M. lepromatosis. Despite significant developments in understanding the biology of leprosy bacilli through genomic approaches, the exact mechanisms of transmission is still unclear and the factors underlying pathological variation of the disease in different patients remain as major gaps in our knowledge about leprosy. Despite these difficulties, the last two decades have seen the development of genotyping procedures based on PCR-sequencing of target loci as well as by the genome-wide analysis of an increasing number of geographically diverse isolates of leprosy bacilli. This has provided a foundation for molecular epidemiology studies that are bringing a better understanding of strain evolution associated with ancient human migrations, and phylogeographical insights about the spread of disease globally. This review discusses the advantages and drawbacks of the main tools available for molecular epidemiological investigations of leprosy and summarizes various methods ranging from PCR-based genotyping to genome-typing techniques. We also describe their main applications in analyzing the short-range and long-range transmission of the disease. Finally, we summarise the current gaps and challenges that remain in the field of molecular epidemiology of leprosy.
Subject(s)
Leprosy/epidemiology , Leprosy/microbiology , Mycobacterium leprae/genetics , Genes, Bacterial , Genome, Bacterial , Genomics/methods , Humans , Leprosy/drug therapy , Leprosy/transmission , Molecular Epidemiology , Mycobacterium leprae/drug effects , Phylogeny , Public Health SurveillanceABSTRACT
Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). In lepromatous leprosy (LL), skin macrophages, harboring extensive bacterial multiplication, gain a distinctive foamy appearance due to increased intracellular lipid load. To determine the mechanism by which M. leprae modifies the lipid homeostasis in host cells, an in vitro M. leprae infection system, using human macrophage precursor THP-1 cells and M. leprae prepared from the footpads of nude mice, was employed. RNA extracted from skin smear samples of patients was used to investigate host gene expressions before and after multidrug therapy (MDT). We found that a cluster of peroxisome proliferator-activated receptor (PPAR) target genes associated with adipocyte differentiation were strongly induced in M. leprae-infected THP-1 cells, with increased intracellular lipid accumulation. PPAR-δ and PPAR-γ expressions were induced by M. leprae infection in a bacterial load-dependent manner, and their proteins underwent nuclear translocalization after infection, indicating activation of PPAR signaling in host cells. Either PPAR-δ or PPAR-γ antagonist abolished the effect of M. leprae to modify host gene expressions and inhibited intracellular lipid accumulation in host cells. M. leprae-specific gene expressions were detected in the skin smear samples both before and after MDT, whereas PPAR target gene expressions were dramatically diminished after MDT. These results suggest that M. leprae infection activates host PPAR signaling to induce an array of adipocyte differentiation-associated genes, leading to accumulation of intracellular lipids to accommodate M. leprae parasitization. Certain PPAR target genes in skin lesions may serve as biomarkers for monitoring treatment efficacy.
Subject(s)
Foam Cells/microbiology , Leprosy/metabolism , Macrophages/microbiology , Mycobacterium leprae/physiology , PPAR delta/metabolism , PPAR gamma/metabolism , Adipocytes/cytology , Adipocytes/metabolism , Adipocytes/microbiology , Animals , Cell Differentiation , Foam Cells/metabolism , Humans , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Leprosy/genetics , Leprosy/microbiology , Lipid Metabolism , Macrophages/metabolism , Mice , Mice, Nude , Mycobacterium leprae/drug effects , PPAR delta/genetics , PPAR gamma/genetics , Skin/metabolism , Skin/microbiologyABSTRACT
Rifampicin resistance is a major therapeutic challenge, particularly in tuberculosis, leprosy, P. aeruginosa and S. aureus infections, where it develops via missense mutations in gene rpoB. Previously we have highlighted that these mutations reduce protein affinities within the RNA polymerase complex, subsequently reducing nucleic acid affinity. Here, we have used these insights to develop a computational rifampicin resistance predictor capable of identifying resistant mutations even outside the well-defined rifampicin resistance determining region (RRDR), using clinical M. tuberculosis sequencing information. Our tool successfully identified up to 90.9% of M. tuberculosis rpoB variants correctly, with sensitivity of 92.2%, specificity of 83.6% and MCC of 0.69, outperforming the current gold-standard GeneXpert-MTB/RIF. We show our model can be translated to other clinically relevant organisms: M. leprae, P. aeruginosa and S. aureus, despite weak sequence identity. Our method was implemented as an interactive tool, SUSPECT-RIF (StrUctural Susceptibility PrEdiCTion for RIFampicin), freely available at https://biosig.unimelb.edu.au/suspect_rif/ .
Subject(s)
Bacterial Proteins/genetics , Drug Resistance, Bacterial/genetics , Machine Learning , Mutation, Missense , Mycobacterium leprae/genetics , Mycobacterium tuberculosis/genetics , Rifampin/pharmacology , Staphylococcus aureus/genetics , Antitubercular Agents/pharmacology , Bacterial Proteins/chemistry , Humans , Leprosy/drug therapy , Leprosy/microbiology , Mycobacterium leprae/drug effects , Mycobacterium tuberculosis/drug effects , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Tuberculosis/drug therapy , Tuberculosis/microbiologySubject(s)
Leprosy/drug therapy , Lipoproteins, HDL/metabolism , Anticholesteremic Agents/pharmacology , Anticholesteremic Agents/therapeutic use , Apolipoprotein A-I/genetics , Apolipoprotein A-I/metabolism , Cholesterol/metabolism , Humans , Leprosy/metabolism , Lipid Metabolism , Mycobacterium leprae/drug effects , Mycobacterium leprae/metabolism , Mycobacterium leprae/pathogenicityABSTRACT
BACKGROUND: Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mouse footpad (MFP) screening assay to aid in the choice of drugs and regimens for clinical trials. METHODOLOGY/PRINCIPAL FINDINGS: Athymic nude mice were inoculated in the footpad (FP) with 6 x 103 viable M. leprae and treated by gastric gavage with a single dose of Rifampin (SDR), Rifampin + Ofloxacin + Minocycline (SD-ROM), or Rifapentine + Minocycline + Moxifloxacin (SD-PMM) or with the proposed PEP++ regimen of three once-monthly doses of Rifampin + Moxifloxacin (RM), Rifampin + Clarithromycin (RC), Rifapentine + Moxifloxacin (PM), or Rifapentine + Clarithromycin (PC). At various times post-treatment, DNA was purified from the FP, and M. leprae were enumerated by RLEP quantitative PCR. A regression analysis was calculated to determine the expected RLEP value if 99.9% of the bacilli were killed after the administration of each regimen. SDR and SD-ROM induced little growth delay in this highly susceptible murine model of subclinical infection. In contrast, SD-PMM delayed measurable M. leprae growth above the inoculum by 8 months. The four multi-dose regimens delayed bacterial growth for >9months post-treatment cessation. CONCLUSIONS/SIGNIFICANCE: The delay in discernable M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3-4 months) and late (8-9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission.
Subject(s)
Asymptomatic Infections/therapy , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Mycobacterium leprae/drug effects , Post-Exposure Prophylaxis/methods , Animals , Bacterial Load/drug effects , Clarithromycin/therapeutic use , Drug Combinations , Leprosy/transmission , Mice , Mice, Nude , Minocycline/therapeutic use , Moxifloxacin/therapeutic use , Mycobacterium leprae/growth & development , Rifampin/analogs & derivatives , Rifampin/therapeutic useABSTRACT
Translational frameshift errors are often deleterious to the synthesis of functional proteins and could therefore be promoted therapeutically to kill bacteria. TrmD (tRNA-(N(1)G37) methyltransferase) is an essential tRNA modification enzyme in bacteria that prevents +1 errors in the reading frame during protein translation and represents an attractive potential target for the development of new antibiotics. Here, we describe the application of a structure-guided fragment-based drug discovery approach to the design of a new class of inhibitors against TrmD in Mycobacterium abscessus. Fragment library screening, followed by structure-guided chemical elaboration of hits, led to the rapid development of drug-like molecules with potent in vitro TrmD inhibitory activity. Several of these compounds exhibit activity against planktonic M. abscessus and M. tuberculosis as well as against intracellular M. abscessus and M. leprae, indicating their potential as the basis for a novel class of broad-spectrum mycobacterial drugs.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Proteins/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , RNA, Transfer/metabolism , tRNA Methyltransferases/antagonists & inhibitors , Anti-Bacterial Agents/chemistry , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Binding Sites , Drug Discovery/methods , Enzyme Inhibitors/chemistry , Molecular Docking Simulation , Mycobacterium abscessus/drug effects , Mycobacterium abscessus/enzymology , Mycobacterium leprae/drug effects , Mycobacterium leprae/enzymology , Protein Binding , tRNA Methyltransferases/chemistry , tRNA Methyltransferases/metabolismABSTRACT
Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Clofazimine/therapeutic use , Leprosy/drug therapy , Mycobacterium Infections, Nontuberculous/drug therapy , Animals , Anti-Bacterial Agents/adverse effects , Drug Resistance, Bacterial , Humans , Leprosy/microbiology , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium leprae/drug effects , Mycobacterium tuberculosis/drug effectsABSTRACT
Leprosy is a chronic infectious disease caused my Mycobacterium leprae that primarily affects peripheral nervous system and extremities and is prevalent in tropical countries. Treatment for leprosy with multidrug regimens is very effective compared to monotherapy especially in multibacillary cases. The three major antileprosy drugs currently in use are 4, 4'-diaminodiphenyl sulfone (DDS, dapsone), rifampicin, and clofazimine. During multidrug therapy, the potent antibiotic rifampicin induces the metabolism of dapsone, which results in decreased plasma half-life of dapsone and its metabolites. Furthermore, rifampicin induces its own metabolism and decreases its half-life during monotherapy. Rifampicin upregulates several hepatic microsomal drug-metabolizing enzymes, especially cytochrome P450 (CYP) family that in turn induce the metabolism of dapsone. Clofazimine lacks significant induction of any drug-metabolizing enzyme including CYP family and does not interact with dapsone metabolism. Rifampicin does not induce clofazimine metabolism during combination treatment. Administration of dapsone in the acetylated form (acedapsone) can release the drug slowly into circulation up to 75 days and could be useful for the effective treatment of paucibacillary cases along with rifampicin. This review summarizes the major aspects of antileprosy drug metabolism and drug interactions and the role of cytochrome P450 family of drug metabolizing enzymes, especially CYP3A4 during multidrug regimens for the treatment of leprosy.
Subject(s)
Acedapsone/blood , Clofazimine/blood , Cytochrome P-450 CYP3A/metabolism , Dapsone/blood , Leprostatic Agents/blood , Leprosy/drug therapy , Rifampin/blood , Acedapsone/pharmacokinetics , Acedapsone/pharmacology , Biological Availability , Biotransformation , Clofazimine/pharmacokinetics , Clofazimine/pharmacology , Dapsone/pharmacokinetics , Dapsone/pharmacology , Drug Interactions , Drug Therapy, Combination , Half-Life , Humans , Leprostatic Agents/pharmacokinetics , Leprostatic Agents/pharmacology , Leprosy/blood , Leprosy/microbiology , Leprosy/pathology , Metabolic Clearance Rate , Metabolic Networks and Pathways/physiology , Mycobacterium leprae/drug effects , Mycobacterium leprae/growth & development , Mycobacterium leprae/pathogenicity , Rifampin/pharmacokinetics , Rifampin/pharmacologyABSTRACT
Using shotgun metagenomics, we identified an imported case of multidrug-resistant Mycobacterium leprae in a Filipino resident of Saudi Arabia in 2017. We determined the phylogenomic lineage (3K1) and identified mutations in rpoB and rrs corresponding to the multidrug-resistance phenotype clinically observed. Metagenomics sequencing can be used to identify multidrug-resistant M. leprae.